Multitarget botanical pharmacotherapy in major depression: a toxic brain hypothesis

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Major depression is a heterogeneous disorder with a significant portion of patients exhibiting resistance to current neurotransmitter-based antidepressant drugs.
• Several biological pathologies, including inflammation, hypercortisolemia, oxidative stress, and impaired angiogenesis, are implicated in depression and may contribute to neurodegeneration and cognitive impairment.
• A unifying neurotoxic brain hypothesis suggests these factors contribute to depression heterogeneity, cognitive decline, and antidepressant drug resistance.

Purpose of the Study:

• To explore the potential of botanical compounds as a multitarget therapeutic strategy for treatment-resistant depression.
• To investigate how the anti-inflammatory, immunoregulatory, antioxidative, and proangiogenic properties of botanical compounds may address underlying pathologies in depression.

Main Methods:

• Review of existing literature on depression pathologies and the biological activities of traditional botanical medicines.
• Comparative analysis of neurotransmitter-based antidepressants versus botanical compounds regarding their mechanisms of action and therapeutic targets.

Main Results:

• Botanical compounds possess diverse biological activities, including anti-inflammatory, immunomodulatory, antioxidative, and proangiogenic effects, often targeting multiple pathways relevant to depression.
• Unlike conventional antidepressants, many botanical compounds can ameliorate the neurotoxic brain environment by addressing inflammation and oxidative stress.
• Some botanical compounds also influence neurotransmission, offering a broader spectrum of action.

Conclusions:

• Botanical compounds, due to their multitarget nature, present a promising avenue for treating patients with major depression who are resistant to conventional therapies.
• A multitarget, multidimensional therapeutic approach incorporating botanical medicine may be a viable solution for addressing the complex pathologies underlying treatment-resistant depression and associated cognitive deficits.